A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)

PHASE2CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

June 24, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

June 30, 2012

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

CEP-33457

CEP-33457 will be administered per dose and schedule specified in the arm description.

DRUG

Placebo

Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.

Trial Locations (86)

1023

Teva Investigational Site 501, Budapest

1090

Teva Investigational Site 102, Brussels

4000

Teva Investigational Site 101, Liège

4032

Teva Investigational Site 502, Debrecen

5530

Teva Investigational Site 100, Yvoir

8900

Teva Investigational Site 500, Zalaegerszeg

11030

Teva Investigational Site 9, Manhasset

12200

Teva Investigational Site 403, Berlin

15213

Teva Investigational Site 26, Pittsburgh

16635

Teva Investigational Site 25, Duncansville

21231

Teva Investigational Site 36, Baltimore

22081

Teva Investigational Site 406, Hamburg

22205

Teva Investigational Site 19, Arlington

27710

Teva Investigational Site 18, Durham

28112

Teva Investigational Site 2, Monroe

28210

Teva Investigational Site 28, Charlotte

29425

Teva Investigational Site 15, Charleston

30281

Teva Investigational Site 38, Stockbridge

30322

Teva Investigational Site 8, Atlanta

30342

Teva Investigational Site 31, Atlanta

33180

Teva Investigational Site 4, Aventura

33334

Teva Investigational Site 35, Fort Lauderdale

33458

Teva Investigational Site 1, Jupiter

33614

Teva Investigational Site 11, Tampa

33765

Teva Investigational Site 32, Clearwater

35233

Teva Investigational Site 27, Birmingham

39008

Teva Investigational Site 752, Santander

40225

Teva Investigational Site 404, Düsseldorf

40504

Teva Investigational Site 37, Lexington

41013

Teva Investigational Site 750, Seville

44093

Teva Investigational Site 302, Nantes

48109

Teva Investigational Site 22, Ann Arbor

52074

Teva Investigational Site 402, Aachen

53226

Teva Investigational Site 33, Milwaukee

55131

Teva Investigational Site 405, Mainz

59000

Teva Investigational Site 301, Lille

67098

Teva Investigational Site 304, Strasbourg

73103

Teva Investigational Site 21, Oklahoma City

73104

Teva Investigational Site 13, Oklahoma City

75013

Teva Investigational Site 300, Paris

75150

Teva Investigational Site 39, Mesquite

75231

Teva Investigational Site 29, Dallas

75674

Teva Investigational Site 303, Paris

76018

Teva Investigational Site 905, Ivano-Frankivsk

76508

Teva Investigational Site 24, Temple

77034

Teva Investigational Site 40, Houston

77074

Teva Investigational Site 6, Houston

78229

Teva Investigational Site 34, San Antonio

79035

Teva Investigational Site 904, Lviv

80045

Teva Investigational Site 30, Aurora

80336

Teva Investigational Site 400, München

83059

Teva Investigational Site 901, Donetsk

83814

Teva Investigational Site 23, Coeur d'Alene

85715

Teva Investigational Site 20, Tucson

90048

Teva Investigational Site 16, Los Angeles

92161

Teva Investigational Site 7, San Diego

94305

Teva Investigational Site 17, Stanford

94578

Teva Investigational Site 14, San Leandro

98104

Teva Investigational Site 12, Seattle

90095-1769

Teva Investigational Site 5, Los Angeles

02111

Teva Investigational Site 10, Boston

27599-7600

Teva Investigational Site 3, Chapel Hill

638 00

Teva Investigational Site 201, Brno

775 20

Teva Investigational Site 200, Olomouc

128 08

Teva Investigational Site 202, Prague

128 50

Teva Investigational Site 203, Prague

01307

Teva Investigational Site 401, Dresden

Teva Investigational Site 751, Dresden

62-069

Teva Investigational Site 603, Dąbrówka

82-300

Teva Investigational Site 600, Elblag

26-200

Teva Investigational Site 602, Gmina Końskie

20-090

Teva Investigational Site 604, Lublin

20-607

Teva Investigational Site 601, Lublin

00-235

Teva Investigational Site 606, Warsaw

50-556

Teva Investigational Site 605, Wroclaw

2720-276

Teva Investigational Site 701, Amadora

3000-075

Teva Investigational Site 702, Coimbra

4099-001

Teva Investigational Site 703, Porto

4200-319

Teva Investigational Site 700, Porto

01601

Teva Investigational Site 900, Kyiv

03151

Teva Investigational Site 902, Kyiv

04107

Teva Investigational Site 903, Kyiv

BA1 1RL

Teva Investigational Site 803, Bath

LS7 4SA

Teva Investigational Site 801, Leeds

SE1 7EH

Teva Investigational Site 800, London

NE7 7DN

Teva Investigational Site 802, Newcastle upon Tyne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon, Inc.

INDUSTRY

NCT01135459 - A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE) | Biotech Hunter | Biotech Hunter